Has Katherine Talcott, MD received payments from drug or device companies?

Yes. Drug and device makers reported $272,116 in general payments to Katherine Talcott, MD across 260 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Katherine Talcott, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Katherine Talcott, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Katherine Talcott, MD

Retina Specialist · Cleveland, OHNPI 1447545587

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Genentech USA, Inc. at 32.2% of the total. 2025 is the largest year on record at $81,725, more than ten times the $1,710 reported in 2019. Among retina specialist clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$272,116in general payments, 2019–2025

Across 260 payments — averaging $1046.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$88K
Astellas Pharma US Inc$40K
Apellis Pharmaceuticals, Inc.$29K
Carl Zeiss Meditec, Inc.$26K
Bausch & Lomb Americas Inc.$19K
Hoffmann-la Roche Limited$14K
plus $56K from 14 others

$582,281in research payments, 2019–2025

Across 86 payments — averaging $6770.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$241K
Novartis$124K
Janssen Research & Development, LLC$85K
Boehringer Ingelheim$57K
AbbVie$26K
Ocular Therapeutix, Inc.$24K
plus $26K from 3 others

What the payments were for

Consulting fees$111,03241%
Speaking & faculty fees$121,28745%
Travel & lodging$28,56110%
Food & beverage$11,2364%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	60	$87,596
Astellas Pharma US Inc	28	$40,036
Apellis Pharmaceuticals, Inc.	24	$28,921
Carl Zeiss Meditec, Inc.	15	$25,868
Bausch & Lomb Americas Inc.	25	$19,342
Hoffmann-la Roche Limited	7	$14,082
Harrow Eye, LLC	12	$12,520
Regeneron	18	$10,933
Genentech, Inc.	12	$7,205
AbbVie	16	$6,566
Alcon	9	$5,559
Alimera Sciences, Inc.	5	$4,021
Regeneron Healthcare Solutions, Inc.	3	$3,087
Eyepoint US, Inc.	9	$2,140
Ocular Therapeutix, Inc.	4	$2,122
Carl Zeiss Meditec USA, Inc.	3	$1,530
Bausch & Lomb, A Division Of Bausch Health US, LLC	4	$317
Novartis	2	$144
Samsara Vision	2	$66
ANI Pharmaceuticals, Inc.	2	$60

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$272,116 in reported general payments places this provider in the 90th percentile of 69 retina specialist providers in Ohio.

See all retina specialist providers in Ohio →

Medicare billing

Part B allowed, 2024

$215,392

Medicare patients

603

Services billed

3,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	146	$6,799
Ciprofloxacin Hcl	85	$1,479
Ketorolac Tromethamine	42	$976
Atropine Sulfate	33	$836
Cyclopentolate Hcl	19	$133
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	12	$130

Paid to pharmacies, not to this prescriber.

Other retina specialist in Cleveland

Sumit SharmaCleveland$428K
Aleksandra RachitskayaCleveland$303K
Suber HuangCleveland$124K
Ananth SastryCleveland$44K
Phoebe LinCleveland$22K
Warren SobolCleveland$5K
Mark SeralyCleveland$3K
Abhishek NaiduCleveland$3K
Mary-Grace ReevesCleveland$2K
Joseph ConeyBeachwood$980K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →